Hepatocellular carcinoma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Future directions

Current research includes the search for the genes that are disregulated in HCC,^[1] protein markers^[2], and other predictive biomarkers.^[3]^[4] As similar research is yielding results in various other malignant diseases, it is hoped that identifying the aberrant genes and the resultant proteins could lead to the identification of pharmacological interventions for HCC.^[5]

References

↑ Genetic research in HCC Stanford Asian Liver Center
↑ Huntington Medical Research Institute News, May 2005
↑ [1] Journal of Clinical Oncology, Special Issue on Molecular Oncology: Receptor-Based Therapy, April 2005
↑ Lau W, Leung T, Ho S, Chan M, Machin D, Lau J, Chan A, Yeo W, Mok T, Yu S, Leung N, Johnson P (1999). “Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial”. Lancet. 353 (9155): 797–801. PMID 10459961.
↑ Thomas M, Zhu A (2005). “Hepatocellular carcinoma: the need for progress”. J Clin Oncol. 23 (13): 2892–9. PMID 15860847.

Template:WikiDoc Sources

[1] Genetic research in HCC Stanford Asian Liver Center

[2] Huntington Medical Research Institute News, May 2005

[3] [1] Journal of Clinical Oncology, Special Issue on Molecular Oncology: Receptor-Based Therapy, April 2005

[Lau_1999-4] Lau W, Leung T, Ho S, Chan M, Machin D, Lau J, Chan A, Yeo W, Mok T, Yu S, Leung N, Johnson P (1999). “Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial”. Lancet. 353 (9155): 797–801. PMID 10459961.

[Thomas_2005-5] Thomas M, Zhu A (2005). “Hepatocellular carcinoma: the need for progress”. J Clin Oncol. 23 (13): 2892–9. PMID 15860847.

[1]

[2]

[3]

[4]

[5]